役員一覧

jpkrcn

企業情報

役員一覧

あなたはここにいる:ホーム > 役員一覧

  • Chunlin Chen, Ph.D. CEO

    Chunlin Chen, Ph。D。 CEO

    Dr. Chen was founder and CEO of Medicilon Inc. Medicilon’s core business is to provide preclinical chemistry, ADMET and biology services to pharmaceutical companies and biotech companies. Prior to founding Medicilon, Dr. Chen had work experience in the USA, as a Staff Investigator at Department of Pharmacokinetics and Metabolism in Vertex Pharmaceuticals and as the Director of Pharmaceutical Department at Parker Hughes Cancer Center.
    In addition, Dr. Chen currently serves as Associate Director for Pharmacokinetics and Drug Metabolism Section of Shanghai Pharmacology Society and visiting Professor for China Pharmaceutical University. Dr. Chen got several awards including Excellent Teacher Award from China Pharmaceutical University, Research Excellent Award from Oklahoma State University and an Excellent returnee award from Chinese government.

  • Guolin Wang, MBA, Board Secretary

    Guolin Wang, MBA, Board Secretary

    Mr. Wang holds a masters degree in business administration from the Open University of Hong Kong. Before joining Shanghai Medicilon Inc. in 2008, Mr. Wang has 9 years of middle and senior level management experience in China Telecom, a large-scale state-owned enterprise, and 6 years of senior management experience in China Unicom, a listed company at home and abroad, as well as 3 years of senior management experience in investment management and health care industry. He served as Deputy General Manager in the municipal branch of China Telecom and China Unicom. He also served as General Manager in a health care investment company. He has rich experience on management and investment.

  • Shuangqing Peng Ph.D  VP of Preclinical

    Shuangqing Peng Ph.D VP of Preclinical

    Postdoctoral fellow in preventive medicine at Peking University and pharmacology at Michigan state university. He is a researcher and doctoral supervisor of academy of military medical sciences, vice chairman of China toxicology society, and executive director of China environmental mutagens society. He was the director of the national center for drug safety evaluation and research and the director of the toxicology evaluation and research center of the PLA institute of disease control and prevention. Undertook the construction of national GLP technology platform, presided over and undertook more than 40 national scientific research projects, including 973 project, 863 project and national science and technology special project of "major new drug creation".
    He has published more than 250 scientific papers, including more than 80 SCI papers, and edited and participated in 9 monographs. It has won 12 national, provincial and ministerial science and technology achievement awards. He was awarded special government allowance by the state council, post allowance for outstanding military personnel, honorary title of "national outstanding scientific and technological worker" by China association for science and technology, and outstanding contribution award by China toxicology society. Training master, doctoral and postdoctoral more than 90. Academic posts include new drug evaluation expert of the state food and drug administration, medical device evaluation expert, new chemical substance evaluation expert of the ministry of environmental protection and deputy editor of ETAP.

  • Xiaodong Zhang Ph.D VP of Preclinical

    Xiaodong Zhang Ph.D VP of Preclinical

    Dr。 Xiaodong Zhang has nearly 20 years of experiences in non-clinical drug safety evaluation。 Dr。 Zhang received his PhD Degree in pharmacology from Institute of Basic Medical Science at Second Military Medical University。 Before joining Medicilon, he was Deputy Director of the Department of Hygiene and Toxicology(Center of Evaluation for Drug Safety) at Second Military Medical University。 As a Director leading the Study Director group to provide regulated GLP non-clinical safety evaluation packages for IND application。 He is an expert in drug consulting group of Center for Drug Evaluation and the member of the Committee of Drug Toxicology & Safety Evaluation, CST, CPA and CNPHAS。

  • Baomin Xin, Ph.D. VP of DMPK & BA

    Baomin Xin, Ph.D. VP of DMPK & BA

    Dr. Baomin Xin has nearly 20 years of experiences in the pharmaceutical industry, serving executive and leadership roles in both the US and China. Before joining Medicilon, Dr. Xin has worked at major pharmaceutical companies and CROs, including Bristol-Myers Squibb (BMS), DuPont Pharmaceutical Company (DPC), and WuXi AppTec. As a Principal Scientist leading the Bioanalytical Research Department at BMS Hopewell site, Dr. Xin has made significant contributions to many discovery programs within the company, especially in the Cardiovascular and Metabolic Disease therapeutic areas, successfully bringing several new medicines to the market including Eliquis (Apixaban).
    Dr. Xin also worked at WuXi AppTec, leading the Bioanalytical Services Department (LC-MS) to provide regulated (GLP/GCP) bioanalysis to support new drug development projects from pharmaceutical companies worldwide, as well as BE projects for the generic drug sector. His team has successfully passed over 20 NMPA inspections and a US FDA inspection without 483s. Dr. Xin got his PhD degree under Professor Milton L Lee at Brigham Young University (BYU).

  • Jianguo Ma, Ph.D. VP of API & Process

    Jianguo Ma, Ph.D. VP of API & Process

    Dr. Ma received B.Sc. and M.Sc. degree in synthetic organic chemistry from Lanzhou University in 1991. He was then awarded his Ph.D degree in 2001 in synthetic organic chemistry from University of Montreal under the supervision of Professor Stephen Hanessian. After two years’ postdoctoral research at Harvard University with Professor Yoshito Kishi, he then began his career in pharmaceutical industry and held various senior scientific positions at Memory pharmaceutical, Sepracorovion and AstraZeneca where he made key contributions to many medicinal chemistry programs in CNS (Alzheimer’s disease, Depression) and Oncology (Raf/MEK dual kinase inhibitors and Antibody-Drug Conjugates, ADC) as well as process chemistry programs. In 2012, he joined Asymchem and had been VP of R&D before he took the CTO (Chief technology Officer) position with Porton in 2014. In 2017, Dr.Ma joined Shanghai Medicilon.

  • Feng Ren, Ph.D. VP of Chemistry & Biology

    Feng Ren, Ph.D. VP of Chemistry & Biology

    Feng Ren, PhD, Vice President, Head of Chemistry and Biology, Medicilon. Dr. Ren joined Medicilon as Vice President, Head of Chemistry and Biology in Feb 2018. Before joining Medicilon, he was Director, Head of Chemistry of Neurodegeneration DPU in GSK. During over 10 years’ career in pharmaceutical industry, Dr. Ren led matrix program teams and delivered a few clinical candidate and pre-candidate compounds for neurodegenerative and neuroinflammatory diseases. Dr. Ren received his PhD degree from the Department of Chemistry and Chemical Biology at Harvard University.

  • Xingquan Ma, Ph.D. VP of Chemistry

    Xingquan Ma, Ph.D. VP of Chemistry

    Dr. Ma was awarded his Ph.D degree in Bioorganic Chemistry from the prestigious Shanghai Institute of Organic Chemistry (SIOC), Chinese Academy of Science in 2001. Dr. Ma was further trained over 5 years in Medical Research in top academia organizations in the United stated, such as, as Associate Researcher in the Scripps Research Institute (TSRI) with Prof. M. G. Finn, and as Postdoctoral Research Fellow at the National Institutes of Health (NIH) with Dr. Pavol Kovac.
    Dr. Ma joined Shanghai ChemPartner, an internationally famous CRO company, as Senior Director in 2006, and joined Shanghai Medicilon as VP of Chemistry in 2008. During this period of 13 years’ CRO research, Dr. Ma significantly contributed to multitudinous drug discover projects, in which currently five compounds were in clinical research stage, and one approved to market by FDA. Dr. Ma has rich experience in carbohydrate chemistry and bio-chemistry, and their related areas. Dr. Ma has over 20 peer-reviewed publications.

  • Jinna Cai, Ph.D. VP of Business Development

    Jinna Cai, Ph.D. VP of Business Development

    Dr. Cai completed her whole high-level education in China Pharmaceutical University from Bachelor to Ph.D. Her doctoral research is cooperative with Institution of Natural Medicine of University of Toyama. Later, she worked in Postdoctoral workstation of Shanghai Institution of Meteria Medica. She contributes herself to new drug development and research for over twenty years. Her research on a Chinese Traditional medicine named Fructus Cnidii was awarded the first award for Science and Technology Progress by State Administration of Traditional Chinese Medicine in 1991 and National Awards for Science and Technology Grade I in 1992. She has served in Huiren Group as director of R&D Center for 5 years in charge of new drug development and application, most of which has been approved. Thereafter, she mastered the whole procedure of new drug application. She was awarded one of the top 10 employees by Huiren Group and Excellent Management Individual of Provincial Technological Center during the “10th –five-year “by Jiangxi Province. Dr. Cai joined Medicilon in July 2008.

彩票平台77 彩王彩票平台 天禧彩票平台 电子彩票平台 汇彩彩票平台 2000彩票平台 星辉彩票平台 爱淘彩票平台 彩票平台89 七七彩票平台网